Pfizer says cancer therapy Braftovi improved survival in late-stage trial

Pfizer (PFE) stock is in focus as colorectal cancer therapy Braftovi as part of a combination regimen succeeds in a ...

Pfizer wins FDA priority review for Hympavzi label expansion

Pfizer (PFE) announced on Friday that the U.S. Food and Drug Administration granted priority review for a marketing ...

Pfizer – Roivant tie-up generates positive mid-stage data for lead asset

Pfizer (PFE) stock in focus as Priovant, a partnership between the company and Roivant Sciences (ROIV) posts positive trial data for its lead asset. Read more here.